Introduction
============

Thiopurine drugs, including 6-mercaptopurine (6-MP) and its prodrug azathioprine (AZA), are commonly used for inflammatory bowel diseases (IBDs), rheumatic disease, acute lymphoblastic leukemia, and autoimmune hepatitis. However, *nucleoside diphosphate-linked moiety X-type motif 15* (*NUDT15*) variants are reported to show a significant association with thiopurine-induced adverse events, particularly in Asians.

*NUDT15* is a 164-amino-acid protein that belongs to the nudix hydrolyses enzyme family, which mainly consists of pyrophosphohydrolases that act on nucleoside diphosphate. The function of this enzyme is to hydrolyze the thiopurine effector metabolites 6-thio-deoxy-GTP (dGTP) and 6-thio-GTP, thereby limiting the efficacy of thiopurines. The *NUDT15* genetic variants disrupt the function of *NUDT15* to varying degrees ([@B1],[@B2]).

We previously analyzed and established a method to accurately identify the risk of codon 139 genotypes in adverse events associated with thiopurines in patients with IBDs, using the results of the MENDEL study in 2018 ([@B3]). However, cases with genetic variants of His/His in codon 139 were excluded. Owing to their rarity, cases with the His/His genetic variant in codon 139 have not been reported in Asian patients ([Table](#t001){ref-type="table"}) ([@B1],[@B3]-[@B7]). Therefore, the treatment strategy for patients with the His/His variant in codon 139 remains unclear.

###### 

NUDT15 Polymorphisms and Thiopurine-associated Leukopenia in Asian Patients.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference   Diagnosis†   Country                       Number of patients   Reported haplotype        Possible diplotype and\
                                                                                                        estimated enzyme activity‡
  ----------- ------------ ----------------------------- -------------------- ------------------------- ------------------------------------------------------------------
  4           IBD          Korea                         978                  p.Arg139Cys               Normal: Arg/Arg, Intermediate: Arg/Cys,\
                                                                                                        Low: Cys/Cys (codon 139)

  1           ALL          Guatemala, Singapore, Japan   270                  p.Arg139Cys\              Normal: ^★^1/^★^1\
                                                                              p.Arg139His\              Intermediate:^★^1/^★^2, ^★^1/^★^3, ^★^1/^★^4, ^★^1/^★^5\
                                                                              p.Val18Ile\               Low: ^★^3/^★^5, ^★^2/^★^3, ^★^3/^★^3
                                                                              p.Val18_Val19insGlyVal    

  5           IBD          China                         732                  p.Arg139Cys\              Normal: ^★^1/^★^1,\
                                                                              p.Val18_Val19insGlyVal\   Intermediate: ^★^1/^★^2, ^★^1/^★^3, ^★^1/^★^5, ^★^1/^★^6\
                                                                              p.Val18Ile                Low: ^★^2/^★^3, ^★^2/^★^6, ^★^3/^★^3, ^★^3/^★^5

  3           IBD          Japan                         1,291                p.Arg139Cys\              Normal: Arg/Arg, Arg/His,\
                                                                              p.Arg139His               Intermediate: Arg/Cys,\
                                                                                                        Low: Cys/His, Cys/Cys (codon 139)

  6           AIH          China                         149                  p.Arg139Cys               Normal: Arg/Arg, Intermediate: Arg/Cys, Low: Cys/Cys (codon 139)

  7           IBD          Japan                         1,245                p.Val18Ile\               N+N: ^★^1/^★^1,\
                                                                              p.Val18_Val19insGlyVal\   N+I: ^★^1/^★^4, ^★^1/^★^5, ^★^1/^★^6,\
                                                                              p.Gly17_Val18del          N+L: ^★^1/^★^2, ^★^1/^★^3, ^★^1/^★^9,\
                                                                                                        I+L: ^★^3/^★^5, ^★^2/^★^6, ^★^2/^★^5, ^★^3/^★^4, ^★^2/^★^4,\
                                                                                                        L+L: ^★^3/^★^3, ^★^2/^★^3, ^★^2/^★^2

  Our case    IBD          Japan                         1                    p.Arg139His               His/His (codon 139)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------

†IBD: inflammatory bowel disease, ALL: acute lymphocytic leukemia, AIH: autoimmune hepatitis

‡N: Normal, I: Intermediate, L: Low enzyme activity; for star allele-based haplotyping, refer to Fig. 2

Case Report
===========

A 40-year-old man who had been diagnosed with ulcerative colitis 6 months earlier was referred to our unit, as he was resistant to induction therapy with 5-aminosalicylic acid, followed by prednisolone and leukocytapheresis. He was hospitalized and administered 4.0 mg/day tacrolimus to resolve abdominal pain and diarrhea and was discharged with the same dose of tacrolimus and 5.0 mg/day prednisolone. *NUDT15* genetic polymorphism testing ([@B1]) revealed the genetic variant of His/His in codon 139. Accordingly, as maintenance therapy, AZA was started at a low dose of 25 mg/day and increased to 50 mg/day after 2 weeks, based on a stable peripheral white blood cell count of 5,650 /μL.

However, on day 40 from the initiation of AZA therapy, he returned to our unit with severe fatigue and anorexia; a blood test showed severe leukopenia, 1,650 /μL (neutrophil count: 21.5 /μL). The 6-thioguanine nucleotide level was within the therapeutic range at 72 pmol/8×10^8^ red blood cells. He suffered from severe alopecia. Upon hospitalization, all medications, including AZA, were ceased, and granulocyte colony-stimulating factor was used to increase his white blood cell count to 4,440 /μL. He was discharged on day 18 and commenced vedolizumab therapy at a starting dose of 300 mg per 2 weeks that was gradually tapered to 300 mg per 8 weeks. He remains in remission.

We analyzed the exonic sequences of *NUDT15* and identified only the His/His variant ([Fig. 1](#g001){ref-type="fig"}); no functional variants in coding regions besides His/His on codon 139 were identified.

![A Sanger sequence chromatogram around codon 139 of *NUDT15*. Exons 1-3 on *NUDT15* were analyzed. The homozygous mutation of c.416G\>A leading to p.Arg139His was observed in our case.](1349-7235-59-1611-g001){#g001}

All procedures performed in the subject were in accordance with the 1964 Declaration of Helsinki. Informed consent was obtained from the participant involved in the study.

Discussion
==========

We herein report a rare case of ulcerative colitis with a His/His mutation; the patient had acute and severe leukopenia (white blood cell count \<2,000 /μL, \<8 weeks) along with severe alopecia. In the MENDEL study, which involved 1,291 patients with IBD with a history of thiopurine usage, Arg/Arg, Arg/His, Arg/Cys, Cys/His, and Cys/Cys genotypes in codon 139 were found in 74.2%, 0.5%, 21.3%, 0.2%, and 3.8%, respectively ([@B3]). The His/His genotype was not observed, so the frequency of this genotype was considered even rarer than those observed. According to the sequence data of 4,700 Japanese individuals in the Tohoku Medical Megabank Organization, the allele frequency of p.Arg139His is 0.0008, so the genotype frequency of His/His is even lower (estimated at 0.00000064) ([@B8]).

All of the haplotypes (refer to [Fig. 2](#g002){ref-type="fig"}) and diplotypes that induce thiopurine-associated leukopenia in Asian patients are summarized in [Table](#t001){ref-type="table"}. The estimated enzyme activity in haplotype cases with p.Arg139His is intermediate, whereas that in diplotype cases with the codon 139 His/His genotype is predicted to be low, regardless of the codon 18 genotype. Therefore, the codon 18 genotype may be ignored when determining the risk of adverse events ([@B7]).

![Star (^★^) allele-based haplotypes of *NUDT15* reported in patients. The diplotypes described in Table are combinations of the haplotypes.](1349-7235-59-1611-g002){#g002}

We suggest cautious treatment with a low dose of 6-MP (5-10 mg/day) or the contraindication of thiopurines when the Arg/Arg genotype in codon 139 is replaced by Cys/His or Cys/Cys, respectively ([@B3]); such treatment lines are also recommended for patients with His/His. Further research will be required to clarify the risk of *NUDT15*-associated thiopurine-induced adverse events. Furthermore, although a case report may not determine the causal association, the accumulation of cases of this rare genotype is expected to help clarify the best management of unique cases.
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